Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials-Reference-Cited by-同舟云学术

Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials

Published:2018-09-20 Issue:2 Volume:10 Page:418-428
ISSN:2040-1116
Container-title:Journal of Diabetes Investigation
language:en
Short-container-title:J Diabetes Investig

Author:

Yabe Daisuke¹²^ORCID,Yasui Atsutaka³,Ji Linong⁴,Lee Moon-Kyu⁵^ORCID,Ma Ronald Ching Wan⁶^ORCID,Chang Tien-Jyun⁷^ORCID,Okamura Tomoo³,Zeller Cordula⁸,Kaspers Stefan⁹,Lee Jisoo⁹,Kohler Sven⁹,Seino Yutaka¹¹⁰^ORCID

Affiliation:

1. Kansai Electric Power Medical Research Institute; Kobe Japan

2. Kyoto University; Kyoto Japan

3. Nippon Boehringer Ingelheim Co., Ltd.; Tokyo Japan

4. Peking University People's Hospital; Beijing China

5. Sungkyunkwan University School of Medicine; Seoul Korea

6. The Chinese University of Hong Kong; Shatin New Territories; Hong Kong SAR China

7. National Taiwan University Hospital; Taipei City Taiwan

8. Boehringer Ingelheim Pharma GmbH & Co. KG; Biberach an der Riss Germany

9. Boehringer Ingelheim International GmbH; Ingelheim Germany

10. Kansai Electric Power Hospital; Osaka Japan

Funder

Boehringer Ingelheim

Eli Lilly and Company

Publisher

Wiley

Subject

General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdi.12910/fullpdf

Reference56 articles.

1. IDF Diabetes Atlas 2017 http://www.diabetesatlas.org/

2. β cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians;Yabe;Curr Diab Rep,2015

3. Type 2 diabetes via β-cell dysfunction in East Asian people;Yabe;Lancet Diabetes Endocrinol,2016

4. Place of sodium-glucose cotransporter-2 inhibitors in East Asian subjects with type 2 diabetes mellitus: insights into the management of Asian phenotype;Lim;J Diabetes Complications,2017

5. Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States;Ma;Ann N Y Acad Sci,2013

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A meta‐analysis of randomized controlled studies examining the effects of sodium‐glucose co‐transporter‐2 inhibitors on peripheral artery disease and risk of amputations;Diabetes, Obesity and Metabolism;2024-09-12

2. Kidney outcomes with SGLT2 inhibitor versus DPP4 inhibitor use in older adults with diabetes;Nephrology Dialysis Transplantation;2024-07-11

3. A multicenter, open‐label, single‐arm trial of the long‐term safety of empagliflozin treatment for refractory diabetes mellitus with insulin resistance (EMPIRE‐02);Journal of Diabetes Investigation;2024-05-04

4. Cost-Effectiveness of Sodium–Glucose Cotransporter-2 Inhibitors for Patients With Heart Failure in China: A New Pillar in Our Pockets, but at What Price?;Journal of Cardiovascular Pharmacology;2024-01

5. Long‐term safety and efficacy of SGLT2 inhibitor use in older east Asians with type 2 diabetes;Journal of Diabetes Investigation;2023-10-10